Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 5Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Neoplasms 3Lung Neoplasms 3Solid Tumors 1Rectal Neoplasms 1Pleural Effusion 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Multiple Myeloma 1Insulin-Like Growth Factor I, Resistance To 1Fallopian Tube Neoplasms 1Advanced Solid Tumors 1Adenocarcinoma 1

Interventions

Gemcitabine 685130-nm albumin-bound paclitaxel 199Fluorouracil 190Oxaliplatin 177Albumin-Bound Paclitaxel 154Capecitabine 137Leucovorin 133Irinotecan 114Radiotherapy 96Taxes 85pembrolizumab 81Cisplatin 73Erlotinib Hydrochloride 70Radiosurgery 69Nivolumab 56Drug Therapy 56Bevacizumab 54Magnetic Resonance Spectroscopy 51Cyclophosphamide 50folfirinox 45Specimen Handling 43Docetaxel 42Cetuximab 40Biopsy 39irinotecan sucrosofate 38S 1 (combination) 36Pancreaticoduodenectomy 35Blood Specimen Collection 34Surgical Procedures, Operative 31Paclitaxel 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × dalotuzumab × Clear all
NCT00769483 2020-09-03

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
81 enrolled 19 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡